WO2008057966A3 - Panel de biomarqueurs de maladie d'artères périphériques - Google Patents

Panel de biomarqueurs de maladie d'artères périphériques Download PDF

Info

Publication number
WO2008057966A3
WO2008057966A3 PCT/US2007/083377 US2007083377W WO2008057966A3 WO 2008057966 A3 WO2008057966 A3 WO 2008057966A3 US 2007083377 W US2007083377 W US 2007083377W WO 2008057966 A3 WO2008057966 A3 WO 2008057966A3
Authority
WO
WIPO (PCT)
Prior art keywords
biomarkers
panel
peripheral arterial
arterial disease
glucose
Prior art date
Application number
PCT/US2007/083377
Other languages
English (en)
Other versions
WO2008057966A2 (fr
Inventor
Eric T Fung
John Cooke
Fujun Zhang
Andrew Wilson
Original Assignee
Vermillion Inc
Univ Leland Stanford Junior
Eric T Fung
John Cooke
Fujun Zhang
Andrew Wilson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vermillion Inc, Univ Leland Stanford Junior, Eric T Fung, John Cooke, Fujun Zhang, Andrew Wilson filed Critical Vermillion Inc
Publication of WO2008057966A2 publication Critical patent/WO2008057966A2/fr
Publication of WO2008057966A3 publication Critical patent/WO2008057966A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G01N33/723—Glycosylated haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des biomarqueurs comprenant de la ß-2-microglobuline, de la cystatine C, hsCRP et du glucose ainsi que les procédés d'utilisation de biomarqueurs pour le diagnostic et/ou l'évaluation du risque de maladie des artères périphériques chez un sujet. Dans certains modes de réalisation, le sujet testé peut souffrir de ou être prédisposé à d'autres maladies du système circulatoire, notamment de la maladie des artères coronaires. L'hémoglobine A1c ou d'autres mandataires pour la mesure des taux de glucose peuvent être substitués pour ou mesurés en plus du glucose dans le contexte de la présente invention.
PCT/US2007/083377 2006-11-01 2007-11-01 Panel de biomarqueurs de maladie d'artères périphériques WO2008057966A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86395106P 2006-11-01 2006-11-01
US60/863,951 2006-11-01
US92567807A 2007-10-26 2007-10-26
US11/925,678 2007-10-26

Publications (2)

Publication Number Publication Date
WO2008057966A2 WO2008057966A2 (fr) 2008-05-15
WO2008057966A3 true WO2008057966A3 (fr) 2008-07-03

Family

ID=39185656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/083377 WO2008057966A2 (fr) 2006-11-01 2007-11-01 Panel de biomarqueurs de maladie d'artères périphériques

Country Status (1)

Country Link
WO (1) WO2008057966A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2469279A1 (fr) 2006-03-11 2012-06-27 The Board Of Trustees Of The Leland Stanford Junior University Cystatin C, lysozyme et bêta-2 microglobuline en tant que biomarqueur d'une maladie des artères périphériques
US8227201B2 (en) 2007-06-27 2012-07-24 Board Of Trustees Of The Leland Stanford Junior University BETA2-microglobulin and C reactive protein (CRP) as biomarkers for peripheral artery disease
WO2016197053A1 (fr) * 2015-06-05 2016-12-08 Beckman Coulter, Inc. Panel de biomarqueurs de l'apnée obstructive du sommeil (aos)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1615036A1 (fr) * 2004-07-07 2006-01-11 F.Hoffmann-La Roche Ag Combinaison de marqueurs pour le diabète de type 1 et 2

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1615036A1 (fr) * 2004-07-07 2006-01-11 F.Hoffmann-La Roche Ag Combinaison de marqueurs pour le diabète de type 1 et 2

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NEDELKOV DOBRIN ET AL: "Design and use of multi-affinity surfaces in biomolecular interaction analysis-mass spectrometry (BIA/MS): A step toward the design of SPR/MS arrays.", JOURNAL OF MOLECULAR RECOGNITION, vol. 16, no. 1, January 2003 (2003-01-01), pages 15 - 19, XP002475577, ISSN: 0952-3499 *
SCHILLINGER MARTIN ET AL: "Joint effects of C-reactive protein and glycated hemoglobin in predicting future cardiovascular events of patients with advanced atherosclerosis.", CIRCULATION 11 NOV 2003, vol. 108, no. 19, 11 November 2003 (2003-11-11), pages 2323 - 2328, XP002475575, ISSN: 1524-4539 *
STANDL E ET AL: "Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: The Munich General Practitioner Project", DIABETOLOGIA, vol. 39, no. 12, 1996, pages 1540 - 1545, XP009098445, ISSN: 0012-186X *

Also Published As

Publication number Publication date
WO2008057966A2 (fr) 2008-05-15

Similar Documents

Publication Publication Date Title
Eastwood et al. Ethnic differences in associations between blood pressure and stroke in South Asian and European men
Ohya et al. Increased pulse wave velocity is associated with low creatinine clearance and proteinuria in a screened cohort
Choi et al. Relationship between brachial-ankle pulse wave velocity and cardiovascular risk factors of the metabolic syndrome
WO2006127861A3 (fr) Diagnostic de maladies et d'etats pathologiques par l'analyse d'echantillons biologiques traites par voie histopathologique a l'aide de preparations tissulaires liquides
ATE545032T1 (de) Diagnose von herz-kreislauf-erkrankung
WO2009090553A3 (fr) Compositions et procédés de détection de peptides post-arrêts
WO2006014628A8 (fr) Procédés d’évaluation des risques de développement de maladies cardio-vasculaires
Namasivayam et al. Influence of aortic pressure wave components determined noninvasively on myocardial oxygen demand in men and women
WO2007147076A3 (fr) Méthodes pour le diagnostic de caractères anormaux fœtaux
WO2008131361A3 (fr) Biocapteurs pour mesurer des analytes dans le liquide interstitiel
Mulè et al. Relationships between mild hyperuricaemia and aortic stiffness in untreated hypertensive patients
WO2010041046A3 (fr) Protéines de granine en tant que marqueurs de maladie cardiaque
WO2006050479A3 (fr) Compositions et methodes pour le diagnostic de troubles du colon
WO2006081521A3 (fr) Methodes pour diagnostic et intervention de troubles hepatiques
EP2546649A3 (fr) Biomarqueurs de la stéatose hépatique et procédés les utilisant
WO2007030928A3 (fr) Methodes permettant de diagnostiquer les etats pathologiques dus au cancer colorectal et au cancer de l'ovaire
WO2005121362A3 (fr) Methode de quantification selective d'isoformes de vegf dans un echantillon biologique et ses utilisations
WO2007032876A3 (fr) Marqueurs biologiques associés à la dégénérescence maculaire liée à l'âge
CA2820841C (fr) Biocapteur competitif a sensibilite accrue
WO2006116083A3 (fr) Combinaison de dosage du 1,5-anhydroglucitol (1,5-ag) et de dosage du a1c/1,5-ag pour la mesure des variations de la glycemie dans le cas d'hyperglycemie generale et post-prandiale chez des patients diabetiques
CA2574417A1 (fr) Timp-2 en tant que cible/marqueur de defaillance de cellules beta
WO2008057966A3 (fr) Panel de biomarqueurs de maladie d'artères périphériques
WO2010138610A3 (fr) Nouveaux sites de phosphorylation de la desmine utiles dans le diagnostic de maladies cardiaques et l'intervention dans le cadre de ces maladies
Bahrainwala et al. Ambulatory Arterial Stiffness Index and circadian blood pressure variability
WO2008125681A8 (fr) Moyens et procédés permettant d'évaluer le risque d'une intervention cardiaque chez des patients souffrant d'une maladie cardiaque coronarienne stable à partir de gdf-15

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07854559

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A OF 21-08-09)

122 Ep: pct application non-entry in european phase

Ref document number: 07854559

Country of ref document: EP

Kind code of ref document: A2